Modern Approaches to Vaccination of Patients with Chronic Liver Diseases and Inflammatory Bowel Diseases against a Novel Coronavirus Infection
https://doi.org/10.22416/1382-4376-2022-32-3-7-11
Abstract
Aim. To analyze the literature data on the peculiarities of vaccination of patients with chronic liver diseases (CLD) and inflammatory bowel diseases (IBD) against COVID-19 infection.
Key findings. It has been shown that many patients with CLD (cirrhosis of the liver, non-alcoholic fatty liver disease) have a higher risk of severe course of a novel coronavirus infection, which necessitates their vaccination. IBD patients are also subject to vaccination, although the immunomodulatory drugs which they take may reduce its effectiveness. In addition, the correct timing of the vaccine administration is of great importance. Vaccination of patients with CLD and IBD is safe, and the frequency of side effects during its implementation does not differ from that in the general population.
Conclusion. Analysis of literature data shows that patients with CLD and IBD are subject to vaccination against COVID-19 infection, which is effective and safe.
About the Authors
A. A. Sheptulin
Sechenov First Moscow State University (Sechenov University)
Arkadiy A. Sheptulin – Dr. Sci. (Med.), Prof., Department of Internal Diseases Propedeutics, Gastroenterology and Hepatology
119435, Moscow, Pogodinskaya str., 1/1
V. T. Ivashkin
Sechenov First Moscow State University (Sechenov University)
Vladimir T. Ivashkin – Dr. Sci. (Med.), RAS Academician, Prof., Departmental Head, Department of Propaedeutics of Internal Diseases, N.V. Chief of Vasilenko Clinic of Internal Disease Propaedeutics, Gastroenterology and Hepatology
119435, Moscow, Pogodinskaya str., 1/1
References
1. Cornberg M., Buti M., Eberhardt C.S., Grossi P.A., Shouvai D. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients. J Hepatol. 2021;74(4):944–51. DOI: 10.1016/j.hep.2021.01.032
2. Ivashkin V.T., Sheptulin A.A., Zolnikova O.Yu., Okhlobystin A.V., Poluektova E.A., Trukhmanov A.S., et al. New Coronavirus Infection (COVID-19) and Digestive System. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):7–13 (In Russ.). DOI: 10.22416/1382-4376-2020-30-3-7
3. Russo F.P., Piano S., Bruno R., Burra P., Puoti M., Masarone M., et al. Italian Association for the Study of the Liver position statement on SARS-COV-2 vaccination. Digestive and Liver Disease. 2021;53:677–81. DOI: 10.1016/j.did.2021.03.013
4. Sharma A., Patnaik I., Kumar A., Gupta R. COVID-19 vaccines in patients with liver disease. J Clin Exp Hepatol. 2021;11(6):720–6. DOI: 10.1016/j.jceh.2021.06.013
5. Fix O.K., Blumberg E.A., Chang K.-M., Chu J., Chung R.T., Goacher E.K., et al. AASLD Expert panel consensus statement: vaccines to prevent COVID-19 infection in patients with liver diseases. Hepatology. 2021. DOI: 10.1002/hep.31751
6. Peck-Radosavljevic M., Burra P., Ferret M.B., Fracasso P., Ricciardiello L., Seufferlein T., et al. Covid-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. UEG Journal. 2021;9:1091–195. DOI: 10.1002/ueg2.12173
7. Wang J., Hou Z., Liu J., Gu Y., Wu Y., Chen Z., et al. Safety and immunogenicity of COVID-19 vaccination in patients with non-alcoholic fatty liver disease (CHESS2101): a multicenter study. J Hepatol. 2021;75(2):439–41. DOI: 10.1016/j.jhep.2021.04.026
8. Moon A.M., Webb G.J., Garcia-Juarez I., Kulkarni A.V., Adali G., Wong D.K., et al. SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination. Hepatology Communications. 2021;0(0):1–9.
9. Prentice R.E., Rentsch C., Al-Ani A., Zhang E., Johnson D., Halliday J., et al. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. Gastro Hep. 2021;3(4):212–26. DOI: 10.10002/ygh2.473
10. Wellens J., Colombel J.-F., Satsangi J.J., Wong S.-Y. SARS-CoV-2 vaccination in IBD: past lessons, current evidence, and future challenges. J Crohn’s Colitis. 2021;15(8):1376–86. DOI: 10.1093/ecco-jcc/jjab046
11. Maconi G., Bosetti C., De Monti A., Boyapati R.K., Shelton E., Piazza N., et al. Risk of COVID-19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021;53(3):263–70. DOI: 10.1016/j.dld.2020.12.013
12. Siegel C.A., Melmed G.Y., McGovern D.P.B., Rai V., Krammer F., Rubin D.T., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70(4):635–40. DOI: 10.1136/gutjnl-2020-324000
13. Lee Y.J., Kim S.-E., Park Y.E., Chang J.Y., Song H.J., Kim D.H., et al. SARS-CoV-2 vaccination for adult patients with inflammatory bowel disease: Expert consensus statements by KASID. Korean J Gastroenterol. 2021;78(2):117–28. DOI: 10.4166/kfg.2021.110
14. Alexander J.L., Moran G.M., Gaya D.R., Raine T., Hart A., Kennedy N.A., et al. SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease Section and IBD Clinical Research Group position statement. Lancet Gastroenterol Hepatol. 2021;6(3):218–24. DOI: 10.1111/apt.16590
15. Dalai R.S., McClure E., Marcus J., Winter R.W., Hamilton M.J., Allegretti J.R. COVID-19 vaccination and perceptions among patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(8):1730–2. DOI: 10.1016/j.cgh.2021.02.004
16. Edelman-Klapper H., Zittan E., Bar-Gill Shitrit A., Rabinowitz B.-G., Goren I., Avni-Biron I., et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNF-alpha. Gastroenterlogy. 2021:S0016-5085(21)03701-X. DOI: 10.1053/j.gastro.2021.10.029
17. Kennedy N.A., Lin S., Goodhand J.R., Chanchlani N., Hamilton B., Bewshea C., et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut. 2021;70(10):1884–93. DOI: 10.1136/gutjnl-2021-324789
18. Khan N., Mahmud N. Effectiveness of SARS-CoV-2 vaccination in a veterams affairs cohort of patients with inflammatory bowel disease with diverse exposure to immunosuppressive medications. Gastroenterology. 2021;161(3):827–36. DOI: 10.1053/j.gastro.2021.05.044
19. Cerna K., Durikova D., Lukas M., Machkova N., Hruba V., Mitrova K., et al. Anti-SARS-CoV-2 vaccination and antibody response in patients with inflammatory bowel disease on immune-modifying therapy; prospective single-tertiary study. Inflamm Bowel Dis. 2021:izab 301. DOI: 10.1093/ibd/izab301
20. Tepasse P.R., Vollenberg R., Nowacki T.M. Vaccination against SARS-CoV-2 in patients with inflammatory bowel diseases: where do we stand? Life (Basel). 2021;11(11):1220. DOI: 10.3390/life11111220
21. Botwin G.J., Li D., Figueiredo J., Cheng S., Braun J., McGovern D.P.B., et al. Adverse events after SARSCoV-2 mRNA vaccination among patients with inflammatory bowel disease. Am J Gastroenterol. 2021;116:1746–51. DOI: 1314309/ajg0000000000001342
Review
For citations:
Sheptulin A.A., Ivashkin V.T. Modern Approaches to Vaccination of Patients with Chronic Liver Diseases and Inflammatory Bowel Diseases against a Novel Coronavirus Infection. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(3):7-11. https://doi.org/10.22416/1382-4376-2022-32-3-7-11
Views:
795
Email this article 
